Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Brunetti, P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Pioglitazone — current profile

Paolo Brunetti

Department of Internal Medicine and Endocrine and Metabolic Studies, University of Perugia, Via E Dal Pozzo, Perugia 06126, Italy, brunetti{at}dimisem.med.unipg.it

Ploglitazone is a thiazolidinedione that specifically reduces insulin resistance in type 2 diabetes. It has been thoroughly investigated in clinical trials and since its market introduction in 1999 has been prescribed to many patients worldwide. In both monotherapy and combination therapy controlled trials, pioglitazone has proved to be an effective anti-hyperglycaemic agent, reducing fasting plasma glucose and displaying dose-dependent, long-term reductions in glycosylated haemoglobin (HbA1C) compared with placebo. Furthermore, in combination studies, insulin resistance and beta-cell function were significantly improved over baseline and placebo, as measured by HOMA. Pioglitazone also significantly reduced the levels of circulating triglycerides and increased high-density lipoprotein cholesterol without affecting total or low-density lipoprotein cholesterol. In all clinical trials, pioglitazone has been well-tolerated. It may be that the effects of pioglitazone on diabetic dyslipidaemia are at least as important as its effects on lowering blood glucose.

Key Words: diabetes • dyslipidaemia • glycaemic control • efficacy • safety • thiazolidinediones.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 1 suppl, S18-S23 (2002)
DOI: 10.1177/14746514020020010501
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?